1. Academic Validation
  2. GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)

GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)

  • ACS Med Chem Lett. 2017 Jun 1;8(7):737-741. doi: 10.1021/acsmedchemlett.7b00132.
Terry D Crawford 1 James E Audia 2 Steve Bellon 2 Daniel J Burdick 1 Archana Bommi-Reddy 2 Alexandre Côté 2 Richard T Cummings 2 Martin Duplessis 2 E Megan Flynn 1 Michael Hewitt 2 Hon-Ren Huang 2 Hariharan Jayaram 2 Ying Jiang 3 Shivangi Joshi 2 James R Kiefer 1 Jeremy Murray 1 Christopher G Nasveschuk 2 Arianne Neiss 2 Eneida Pardo 2 F Anthony Romero 1 Peter Sandy 2 Robert J Sims 3rd 2 Yong Tang 2 Alexander M Taylor 2 Vickie Tsui 1 Jian Wang 3 Shumei Wang 1 Yongyun Wang 3 Zhaowu Xu 3 Laura Zawadzke 2 Xiaoqin Zhu 3 Brian K Albrecht 2 Steven R Magnuson 1 Andrea G Cochran 1
Affiliations

Affiliations

  • 1 Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • 2 Constellation Pharmaceuticals, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States.
  • 3 Wuxi Apptec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China.
Abstract

The biological function of bromodomains, epigenetic readers of acetylated lysine residues, remains largely unknown. Herein we report our efforts to discover a potent and selective inhibitor of the bromodomain of cat eye syndrome chromosome region candidate 2 (CECR2). Screening of our internal medicinal chemistry collection led to the identification of a pyrrolopyridone chemical lead, and subsequent structure-based drug design led to a potent and selective CECR2 bromodomain inhibitor (GNE-886) suitable for use as an in vitro tool compound.

Keywords

Bromodomain; CECR2; Epigenetics; Probe.

Figures
Products